New pill shows promise for tough blood cancers in early trial

NCT ID NCT04883957

Ongoing Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks tumors, but this is not a cure and ongoing management is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma indolent B-cell non-Hodgkin lymphoma marginal zone lymphoma neoplasm of mature B-cells

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MATURE B-CELL MALIGNANCIES

Contacts and locations

Locations

Affiliated Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, 200032, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Peking University Peoples Hospital

Beijing, Beijing Municipality, 100044, China
Shenzhen Peoples Hospital

Shenzhen, Guangdong, 518020, China
Sun Yat Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University Branch Donghu

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.